NYSE : ABBV
AbbVie Inc. — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 294.89 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 521.11B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 521.11B |
| Enterprise Value | 585.42B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Oct 15, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 76.60% |
| Float | 1.76B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 50.77 |
| Forward PE | 18.80 |
| PS Ratio | 7.89 |
| Forward PS | 7.31 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.62 |
| P/OCF Ratio | 26.71 |
| PEG Ratio | 1.39 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 56.83 |
| EV / Sales | 8.87 |
| EV / EBITDA | 18.46 |
| EV / EBIT | 24.32 |
| EV / FCF | 32.15 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.81 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.21 |
| Debt / FCF | 3.89 |
| Interest Coverage | 8.21 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.51% |
| Return on Invested Capital (ROIC) | 17.29% |
| Return on Capital Employed (ROCE) | 24.49% |
| Weighted Average Cost of Capital (WACC) | 5.07% |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | $180,737 |
| Employee Count | 57,000 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.47 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.47B |
| Effective Tax Rate | 19.24% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +30.98% |
| 50-Day Moving Average | 269.29 |
| 200-Day Moving Average | 237.10 |
| Relative Strength Index (RSI) | 72.78 |
| Average Volume (20 Days) | 5,225,936 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15.58M |
| Short Previous Month | 19.49M |
| Short % of Shares Out | 0.88% |
| Short % of Float | 0.88% |
| Short Ratio (days to cover) | 3.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 66.01B |
| Gross Profit | 48.67B |
| Operating Income | 24.07B |
| Pretax Income | 12.81B |
| Net Income | 10.30B |
| EBITDA | 31.71B |
| EBIT | 24.07B |
| Earnings Per Share (EPS) | $5.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.57B |
| Total Debt | 70.89B |
| Net Cash | -64.32B |
| Net Cash Per Share | -$36.40 |
| Equity (Book Value) | -5.89B |
| Book Value Per Share | -3.36 |
| Working Capital | -7.97B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 19.51B |
| Capital Expenditures | -1.30B |
| Depreciation & Amortization | 7.64B |
| Net Borrowing | 418.00M |
| Free Cash Flow | 18.21B |
| FCF Per Share | $10.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | 73.72% |
| Operating Margin | 36.46% |
| Pretax Margin | 19.41% |
| Profit Margin | 15.67% |
| EBITDA Margin | 48.03% |
| EBIT Margin | 36.46% |
| FCF Margin | 28.28% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $6.92 |
| Dividend Yield | 2.35% |
| Dividend Growth (YoY) | 5.49% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 119.14% |
| FCF Payout Ratio | 67.15% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.35% |
| Earnings Yield | 1.97% |
| FCF Yield | 3.49% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $298.50 |
| Price Target Difference | 1.22% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | 9.17% |
| EPS Growth Forecast (3Y) | 21.71% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |